Key Takeaway: Legend Biotech reported a 50% increase in net trade sales of CARVYKTI, reaching approximately $657 million in the second quarter of 2026. The company expanded CARVYKTI's availability to 348 sites across 19 global markets, including a successful launch in Ireland. Additionally, Legend achieved its first clinical proof-of-concept for LB2501.
Market Sentiment Analysis
POSITIVE FACTORS
CARVYKTI net trade sales increased by 50% compared to Q2 2025.
Expanded availability of CARVYKTI to 348 global sites and 19 markets.
Successful launch of CARVYKTI in Ireland.
Achieved first clinical proof-of-concept for LB2501.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+118%
120-day peak, hindsight
Typical move
18.4%
average across 6 past catalysts
Lead asset
LUCAR-DKS1 NK cells
Phase 1 · Relapsed/Refractory Autoimmune Diseases
Full Press Release Details
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI ® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, an
Frequently Asked Questions
What were Legend Biotech's Q2 2026 sales figures?
Legend Biotech reported net trade sales of approximately $657 million.
How much did CARVYKTI sales increase compared to Q2 2025?
CARVYKTI sales increased by 50% compared to the second quarter of 2025.
In how many markets is CARVYKTI available?
CARVYKTI is now available in 19 global markets.
What is LB2501?
LB2501 is a product for which Legend Biotech achieved its first clinical proof-of-concept.